Phylogene news

News

Microbiome and cancer

If you missed out our October Awareness month posts on Linked In, now the time to catch-up! Post were addressing the role of microbiota in cancers, from his emerging role in Tumor Microenvironment to his singularity in Breast Cancer tissue.

Phylogene is proud to participate in raising awareness of breast cancer during Breast Cancer Awareness Month!

Exploring the Emerging Role of the Gut Microbiota and Tumor Microenvironment in Cancer Immunotherapy

The tumor microenvironment (TME) is a complex ecosystem, which includes many different types of cells, abnormal vascular systems, and immunosuppressive cytokines. TME serves an important function in tumor tolerance and escapes from immune surveillance leading to tumor progression (1).

In few words:

  • Gut microbiota can shape TME by regulating the immune and hormonal factors of the whole host, in other words, host gut microbiota is emerging as a critical modulator of the TME.
  • An in-depth understanding of TME, its role and related molecules will provide important insights into the biological behavior of different tumor types.

The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View

Excellent review asking pragmatic questions regarding the role of microbiome in cancers and the need to use multiomic approaches for better data integration (2).

“Outstanding Questions”:

  • What other members of the human microbiome beyond bacteria –archaea, fungi, and viruses (including bacteriophages) – are important for cancer?
  • How can we integrate microbial composition and function with other relevant data such as habitat, host information, and other variables quantified by omic approaches?
  • Does the human microbiome play a role in the link between migration and cancer incidence?
  • Why does the success of microbiota transplants vary from patient to patient?
  • Can the ability of gut microbes to influence the central nervous system be leveraged to manage pain in cancer patients or even cancer development?
  • Can we engineer microbiomes to turn immunotherapy nonresponders into responders?

Exploring the Potential of Breast Microbiota as Biomarker for Breast Cancer and Therapeutic Response

The human microbiome is a mysterious treasure of the body playing endless important roles in the host’s metabolism, digestion, immunity and well-being. On the other hand, it actively participates in the development of a variety of pathological conditions including Cancer (3).

This review highlights few interesting findings regarding microbiota in breast cancer:

  • Breast cancer tissue contains its own unique microbiota
  • Preclinical data indicates that breast microbiota dysbiosis contributes to breast cancer initiation and progression
  • Differences in breast microbiota composition have been found between breast cancer subtypes and disease severities that may contribute to immunosuppression
  • Interactions between breast microbiota, gut microbiota, and immune system (Breast – Gut Axis)

Microbiome and Breast Cancer: New Role for an Ancient Population

The human microbiome is a mysterious treasure of the body playing endless important roles in the host’s metabolism, digestion, immunity and well-being. Although the multiple evidences liking the microbiome to Breast Cancer (BC) are undeniable, there are essential questions to be answered to unlock the exact role of the microbiome in the development and treatment of BC (4).

This review aimed at evaluating:

  • The role of the microbiome as a risk factor in the occurrence of BC investigating and assessing the impact of the altered composition of breast, guts, and milk microbiome in the physiological status of normal breast as well as cancerous or non-cancerous breast lesions.
  • The role of microbiome in the development and maintenance of inflammation
  • Clinical and therapeutic applications of the microbiome- e.g., probiotics, microbiome genome modulation, and engineered microbiome enzymes in the management of BC

What is the role of microbiota in cancers? Protectant or enhancer of the disease?

With Phylogene you can characterize bacterial populations in Tumor microenvironment and elucidate metabolic pathways. Just think out of the box!

  • Bacterial 16s rDNA and fungal ITS sequencing with OUT-based estimation to investigate microbial diversity and determine taxonomic composition.
  • High-resolution nano LC-MS/MS quantitative metaproteomics and HolXplore™ data processing, for host-microbiota interactions discovery.

(1).https://www.frontiersin.org/articles/10.3389/fimmu.2020.612202/full

(2).https://www.cell.com/trends/cancer/fulltext/S2405-8033(20)30017-0

(3).https://doi.org/10.1016/j.ajpath.2021.02.020

(4).https://www.frontiersin.org/articles/10.3389/fonc.2020.00120/full

PHYLOGENE

62, Route Nationale 113

30620 BERNIS

Tel : +33 4 66 04 77 99 Fax : +33 4 66 04 77 97

e-mail : r.arnaud@phylogene.com

web : www.phylogene.com

For our latest News, articles and activities please follow us on LinkedIn!

Read more

News

Publication in International Journal of Cosmetic Science

Our new publication which shows how LC-MS/MS proteomics can reveal in an untargeted way the modifications of the intracellular fibroblast collagen proteome induced by differential treatments.

Read more

News

Skinobs Focus on Hair care substantiation

How to characterize microbiota metabolism on scalp

Read more

News

Our PUBLICATION in COSMETICOBS

Our publication in Cosmeticobs about modes of action on skin and its microbiota using omics techniques

Read more

News

BIO Digital 2021

PHYLOGENE will attend BIO Digital June 10-11 & 14-18, 2021 and One-on-One Partnering.
We would be pleased to share some time with you to talk about your projects on which we could be useful.

Read more

News

LAUNCHING OF THE "ALLIANCE PROMOTION MICROBIOTE"

Phylogene is proud to be part of the "Alliance Promotion Microbiote”.

This initiative should gather major microbiome industry actors in efforts to put the microbiome at the heart of diagnostic and therapeutic strategies for better care.

Read more

News

OUR EVENTS

Thank you for the time spent with us at BIOFIT 2020, Oncology virtual partnering meeting 2021, NUTREVENT 2021, we look forward to seeing you again next edition!

Read more

News

PUBLICATION IN HEMATOLOGY

A new publication in hematology based on plasma samples analysed by nanoLC-MS/MS proteomics method of choice for biomarker generating

Read more

News

OUR POSTER AT IFSCC 2020 ABOUT HUMAN INNERVATED REBUILT EPIDERMIS AND PROTEOMICS

Our proteomics and bioinformatics study with partners contributed to understand the structure and working of the new human innervated reconstituted epidermis in testing ingredients effects

Read more

News

OUR POSTER/7th MICROBIOME AND PROBIOTICS R&D AND BUSINESS COLLABORATION FORUM: EUROPE 30th Nov -1st Dec 2020

We look forward to talking to you about omics and bioinformatics for active molecules, pharmabiotics, diets or nutritional ingredients mechanisms of action and discovery on microbiotas. See an example of our tools presented in our poster.

http://www.global-engage.com/event/microbiota/#agenda

Read more

CRO in omics and associated bioinformatics including discovery in pharma, biopharma and cosmetics or food allergens detection in food industry

Phylogene, founded 1999, is a biotechnology servicing company using genomics, transcriptomics, proteomics, metabolomics and bioinformatics techniques with the objective of developing methods of identification and ways to authenticate, or discover biological effects .
The applications are mainly the service to the food industry, health industry including in vitro diagnostics, cosmetics, environment industry as expertise or analysis and as kit developer to the diagnostics industry.


Accreditation COFRAC n1-2128-testing- Scope available on www.cofrac.fr

Our partners

They trusted us